AstraZeneca will hold the registration and manufacture Pulmicort Respules, while Glenmark will commercialize the product in Columbia
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Fast, flexible space allows clinical trials to start when needed. A trial can become operational, pivot or scale without traditional capital building expenditures
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
Hitz shall assume new role from January 17th, 2022
He has over 22 years of experience in pharmaceutical sales & business development
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
Subscribe To Our Newsletter & Stay Updated
